Pumitamig Delivers Promising Efficacy with Positive PFS Trend in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Interim data from a global, randomized Phase 2 clinical trial (NCT06449209) on pumitamig (BNT327, BMS986545; Bristol Myers Squibb, BioNTech), an investigational bispecific antibody targeting PD-L1 x VEGF-A, have shown encouraging antitumor responses and a positive trend in progression-free survival (PFS) in patients with extensive-stage small cell lung cancer (ES-SCLC). These promising results were presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer in Barcelona, Spain.

SCLC is an exceptionally aggressive form of lung cancer, characterized by rapid growth, a poor prognosis, and a 5-year relative survival rate of just 5% in advanced stages. Despite initial responses to standard-of-care treatments, most patients experience progression within months, underscoring an urgent need for novel therapies.

Pumitamig: A Novel, Dual-Action Mechanism

Pumitamig represents a novel approach, combining two complementary and validated mechanisms in oncology into a single molecule:

Anti-VEGF-A Activity: It blocks VEGF-A, which starves tumor cells of blood and oxygen (antiangiogenesis effect) and reverses the tumor’s immunosuppressive microenvironment.
PD-L1 Targeting: It targets PD-L1 on tumor cells, aiming to localize anti-VEGF activity specifically within the tumor microenvironment. This targeted approach is intended to enhance therapeutic precision and minimize systemic exposure, potentially reducing off-target adverse effects.

By disrupting both tumor blood supply and immune evasion pathways, pumitamig aims to prevent tumor growth and proliferation more effectively.

Interim Phase 2 Trial Results (BNT327-01) Show Strong Responses

The BNT327-01 trial evaluated pumitamig in three cohorts:

Cohort 1: Untreated ES-SCLC patients (pumitamig + chemotherapy)
Cohort 2 & 3: ES-SCLC patients who progressed on first- or second-line treatment (pumitamig + paclitaxel or topotecan)

The interim analysis focused on 43 untreated ES-SCLC patients in Cohort 1, who received pumitamig with standard-of-care chemotherapy at two dose levels. Key findings from the 38 efficacy-evaluable patients (as of August 7, 2025, data cut-off) include:

Objective Response Rate (ORR): Approximately 76.3% (with 85.0% at the 20 mg/kg dose and 66.7% at the 30 mg/kg dose).
Disease Control Rate (DCR): 100%.
Tumor Shrinkage: Mean best percentage change in tumor size showed a shrinkage of approximately 56.7%, with 89.5% of patients achieving early tumor shrinkage.
Median Progression-Free Survival (PFS): 6.8 months (6.3 months at 20 mg/kg and 7.0 months at 30 mg/kg).
Overall Survival (OS): Median OS data was not yet mature at the time of analysis.

These response rates and early PFS figures are highly encouraging, suggesting that pumitamig could offer more durable antitumor responses compared to current standards of care.

Manageable Safety Profile and Future Directions

Pumitamig plus chemotherapy demonstrated a manageable safety profile, with no new safety signals beyond those typically associated with chemotherapy agents and anti-PD-L1/anti-VEGF monotherapies. The discontinuation rate due to adverse events was low (14%). Grade 3 or higher treatment-emergent adverse events related to pumitamig were reported in 1 patient at the lower dose level and 5 patients at the higher dose level.

This promising interim data supports the ongoing investigation of pumitamig in a larger trial to validate its potential as a new standard of care for ES-SCLC. Bristol Myers Squibb and BioNTech are actively exploring pumitamig’s potential across more than 10 solid tumor indications, with over 20 ongoing or planned clinical trials. This dual-targeting approach highlights a significant step towards overcoming some of the biggest treatment challenges in highly aggressive cancers.